Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study for Identifying Optimal Simvastatin Formulation for Uniform Time to Maximum Plasma Concentration

This study has been terminated.
(Low recruitment rate)
Stanford University
Information provided by (Responsible Party):
University of Zurich Identifier:
First received: July 10, 2012
Last updated: June 2, 2015
Last verified: May 2015
The inter- and intra-variability in the pharmacokinetic parameters of different formulations and doses of simvastatin in healthy subjects and in subjects with celiac disease in remission will be evaluated. Additionally, baseline values of pharmacokinetic parameters of simvastatin for both study groups will be determined.

Condition Intervention Phase
Celiac Disease
Drug: Simvastatin
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: A Phase I, Randomized, Open Label, Mono-centered, Prospective Study to Evaluate the Pharmacokinetics of Different Formulations and Doses of Simvastatin in Healthy Subjects and in Subjects With Celiac Disease in Remission

Resource links provided by NLM:

Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • Peak plasma concentration (Cmax) of simvastatin [ Time Frame: 0, 15, 30, 60, 90, 120, 180 minutes post-dose ]
    Determination of time-dependent concentrations of simvastatin in collected serum of each subject following oral administration of two different formulations and two different doses of simvastatin

Enrollment: 12
Study Start Date: July 2012
Study Completion Date: February 2014
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Liquid formulation of Simvastatin Drug: Simvastatin
Comparison of pharmacokinetic parameters of different formulations (liquid vs tablet) and doses (20 or 40 mg) of simvastatin after single oral administration of the drug
Active Comparator: Tablet formulation of Simvastatin Drug: Simvastatin
Comparison of pharmacokinetic parameters of different formulations (liquid vs tablet) and doses (20 or 40 mg) of simvastatin after single oral administration of the drug


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion criteria:

  • If the subject is female, she is eligible to enter and participate in this study if she is physiologically incapable of becoming pregnant or has a negative urine pregnancy test at screening and at baseline visit
  • Negative Serology for Hepatitis B/C, HIV
  • Non-OATP1B1*5 carriers
  • Negative Serology for anti-transglutaminase IgA antibody, and normal levels of total IgA
  • For subjects with celiac disease, also

    • Diagnosis of celiac disease confirmed by medical history, histological evaluation of small intestinal mucosa on small bowel biopsy, and abnormal anti-transglutaminase antibody titers
    • Followed a gluten-free diet for at least one year, as verified by normal anti-transglutaminase antibody levels, Marsh 0-1 score on a follow-up biopsy within the past 12 months, and absence of any clinical signs or symptoms of celiac disease observed at diagnosis

Exclusion criteria:

  • Current smoker or quit smoking less than 2 years ago
  • Female breastfeeding or disagrees to use an effective mechanical contraceptive method (e.g. diaphragm or nonhormonal intrauterine device in combination with preservative)
  • Presence of any known on-going disease which is judged to be relevant according to the investigator, besides celiac disease for the cohort of celiac patients in remission
  • State after operations of the stomach or bowel (exception: appendectomy)
  • Participation in any other clinical trial with investigational or approved drugs within the last month before the study
  • Regular alcohol consumption of more than 25 g / day
  • Use of any prescription or non-prescription drugs (including herbal supplements) must be discontinued 30 days prior to study (exceptions: paracetamol and NSAIDs, not taken longer than 2 days in a row and not taken within the last 3 days before the study)
  • Consumption of grapefruit, star fruit, grapefruit juice, or star fruit juice must be discontinued 7 days prior to the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01642862

University Hospital Zurich, University Hospital Zurich, Gastroenterology and Hepatology
Zurich, ZH, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Stanford University
Principal Investigator: Gerhard Rogler, Prof MD PhD University Hospital Zurich, Gastroenterology and Hepatology
  More Information

Responsible Party: University of Zurich Identifier: NCT01642862     History of Changes
Other Study ID Numbers: CYPCEL-1103
Study First Received: July 10, 2012
Last Updated: June 2, 2015

Additional relevant MeSH terms:
Celiac Disease
Malabsorption Syndromes
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Metabolic Diseases
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors processed this record on May 25, 2017